Clinical trials: Rituximab, completed
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-Cell Lymphoma
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
This is a randomized, open-label, active-control, parallel-group, multicenter, multinational Phase 2 Study of the efficacy and safety of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab…
- Trial name
- NCT01040871
- Testing
- VELCADE, Rituximab, Cyclophosphamide
- Where
- Belgium
- Volunteers
- 164 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma
Non-Hodgkin Lymphoma in Elderly Patients Above the Age of 80 in the Rituximab Era
This is an exploratory analysis that is investigating the pattern of care in patients over the age of 80 who were diagnosed with non-Hodgkin lymphoma (NHL).
- Trial name
- NCT00902434
- Volunteers
- 50 people
- Sponsor
- Oncology Specialists, S.C.
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
This phase I trial studies the side effects and best dose of avelumab, utomilumab, rituximab, ibrutinib, and combination chemotherapy in treating patients with diffuse large B-cell lymphoma or mantle cell lymphoma that has come…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Trial name
- NCT03440567
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Lymphoma
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00040950
- Testing
- rituximab, agatolimod sodium
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Bullous Pemphigoid
Rituximab in the Treatment of Patients With Bullous Pemphigoid
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
- Trial name
- NCT00286325
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Idiopathic Membranous Nephropathy
MEmbranous Nephropathy Trial Of Rituximab
The primary outcome of this study is to determine whether or not the B cell targeting with Rituximab is non-inferior or more effective than Cyclosporine in inducing long term remission of proteinuria.
- Trial name
- MENTOR (NCT01180036)
- Testing
- Rituximab, Cyclosporine
- Where
- 21 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Mayo Clinic
Rheumatoid Arthritis
An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis
This prospective observational study aims to evaluate safety, application and onset of effect of rituximab in clinical routine treatment of severe active rheumatoid arthritis during the first 6 months (in case of re-therapy: 12…
- Trial name
- NCT01071798
- Testing
- Rituximab
- Where
- Germany
- Volunteers
- 1,653 people
- Sponsor
- Hoffmann-La Roche
Large B Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
This randomized phase III trial studies rituximab when given together with two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell non-Hodgkin's lymphoma.
- Trial name
- NCT00118209
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 47 sites in United States
- Volunteers
- 524 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Primary Central Nervous System Lymphoma
A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL
This is a single arm, single center, open label pilot study of Orelabrutinib combined with Rituximab, high-dose (HD) Methotrexate and Dexamethasone in newly-diagnosed primary central nervous system lymphpoma (PCNSL).
- Trial name
- ORMD2021 (NCT05036577)
- Testing
- Orelabrutinib, Rituximab, Methotrexate (MTX)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Huashan Hospital
Lymphoma, Non-Hodgkin
Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
- Trial name
- NCT00045864
- Testing
- Recombinant Human Interleukin-2 and Rituximab
- Where
- 33 sites in United States
- Sponsor
- Chiron Corporation
Mantle Cell Lymphoma
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
The purpose of this study is to find out whether combining a short course of chemotherapy (Fludarabine, Mitoxantrone and Rituximab) followed by Zevalin will be effective in treating relapsed mantle cell lymphoma.
- Trial name
- NCT00119730
- Testing
- Fludarabine, Mitoxantrone, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Hepatitis C, Vasculitis
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
The purpose of this study is to assess the efficacy of Rituximab (anti-CD20) in the treatment of patients with hepatitis C associated cryoglobulinemic vasculitis (HCV-CV) who have failed or are intolerant to…
- Trial name
- NCT00029107
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
This phase II trial studies how well an umbilical cord blood transplant with added sugar works with chemotherapy and radiation therapy in treating patients with leukemia or lymphoma.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03096782
- Testing
- Anti-Thymocyte Globulin, Busulfan, Clofarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be…
- Trial name
- NCT00242996
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B-Cell Lymphoma, Follicular Lymphoma
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma.
- Conditions
- B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
- Trial name
- NCT00085696
- Testing
- VELCADE and rituximab
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma
Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab
SUMMARY: This is a multi-center open label study to evaluate the safety and effectiveness of Treanda™ (also known as bendamustine HCl or SDX-105) in patients who have indolent Non-Hodgkin's lymphoma and have relapsed within a…
- Trial name
- NCT00139841
- Testing
- Bendamustine HCl
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Cephalon
Multiple Sclerosis
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
- Trial name
- NCT00097188
- Testing
- rituximab
- Where
- 31 sites in United States
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
To determine the efficacy (response rate) produced by the combination of Gemzar, Novantrone, and Rituxan in relapsed or refractory MCL
- Trial name
- NCT00656084
- Testing
- gemcitabine, mitoxantrone, rituximab
- Volunteers
- 16 people
- Sponsor
- US Oncology Research
Lymphocytic Leukemia, Chronic
A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe)
This randomized, open-label, parallel group study will assess the effect on response rate and the safety of MabThera added to either bendamustine or chlorambucil in patients with chronic lymphocytic leukemia.
- Trial name
- NCT01056510
- Testing
- bendamustine, chlorambucil, rituximab [MabThera/Rituxan]
- Where
- 85 sites in Finland, France and 6 more
- Volunteers
- 357 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.